The treatment of climacteric symptoms;Therapie von Beschwerden in den Wechseljahren

Deutsches Arzteblatt International

Volumn 109, Issue 17, 2012, Pages 316-323

  Ortmann, Olaf ^a   Lattrich, Claus ^a  

^a CARITAS KRANKENHAUS ST JOSEF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CEREBROVASCULAR ACCIDENT; ESTROGEN THERAPY; FEMALE; GALLBLADDER DISEASE; HORMONAL THERAPY; HUMAN; MENOPAUSAL SYNDROME; MENOPAUSE; PHYSICIAN; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOEMBOLISM; URINARY TRACT INFECTION; VAGINA ATROPHY; VAGINAL DRYNESS;

EID: 84903362861     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2012.0316     Document Type: Article

References (24)

1. Ortmann O, Dören M, Windler E: Hormone therapy in perimeno-pause and postmenopause (HT): Interdisciplinary S3 Guideline, Association of the Scientific Medical Societies in Germany AWMF 015/062-short version. Arch Gynecol Obstet 2011; 284: 343-55.
2. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe: S3-Leitli-nie "Hormontherapie in der Peri-und Postmenopause". www.dggg. de/fileadmin/public-docs/Leitlinien/2-1-4-ht-lang-hp.pdf
3. Freeman EW, Sammel MD, Lin H, Liu Z, Gracia CR: Duration of me-nopausal hot flushes and associated risk factors. Obstetrics and gy-necology 2011; 117: 1095-104.
4. Arneimittelkommission der deutschen Ärzteschaft: Hormontherapie im Klimakterium www.akdae.de/Arzneimitteltherapie/TE/A-Z/PDF/Hormontherapie.pdf
5. New Zealand Guidelines Group. The appropriate prescribing of hormone replacement therapy. Bestpractice evidence-based guideline, Wellington: New Zealand Guidelines Group 2001.
6. Utian WH, Archer D F, Bachmann GA, et al.: Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008; 15(4 Pt 1): 584-602.
7. Maclennan AH, Broadbent JL, Lester S, Moore V: Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane database of systematic reviews 2004; (4): CD002978.
8. Vesco KK, Haney EM, Humphrey L, Fu R, Nelson HD: Influence of menopause on mood: a systematic review of cohort studies. Climacteric: the journal of the International Menopause Society 2007; 10: 448-65.
9. Nelson HD, Vesco KK, Haney E, et al.: Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA: the journal of the American Medical Association 2006; 295: 2057-71.
10. Fotherby K: Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. Contraception 1996; 54: 59-69.
11. NAMS: Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17: 242-55.
12. Suckling J, Lethaby A, Kennedy R: Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane database of systematic reviews 2003; (4): CD001500.
13. Moehrer B, Hextall A, Jackson S: Oestrogens for urinary incontinence in women. Cochrane database of systematic reviews 2003; (2): CD001405.
14. Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T: Postmenopausal hormones and incontinence: the Heart and Estro-gen/Progestin Replacement Study. Obstetrics and gynecology 2001; 97: 116-20.
15. Barnabei VM, Cochrane BB, Aragaki AK, et al.: Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstetrics and gynecology 2005; 105(5 Pt 1): 1063-73.
16. Perrotta C, Aznar M, Mejia R, Albert X, Ng CW: Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane database of systematic reviews 2008; 2: CD005131.
17. Torgerson DJ, Bell-Syer SE: Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285: 2891-7.
18. Wells G, Tugwell P, Shea B, et al.: Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002; 23: 529-39.
19. Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA: Long term hormone therapy for perimenopausal and postmenopau-sal women. Cochrane database of systematic reviews 2005; (3): CD004143.
20. Anderson GL, Limacher M, Assaf AR, et al.: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12.
21. LaCroix AZ, Chlebowski RT, Manson JE, et al.: Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011; 305: 1305-14.
22. Morch LS, Lokkegaard E, Andreasen AH, Kruger-Kjaer S, Lidegaard O: Hormone therapy and ovarian cancer. JAMA 2009; 302: 298-305.
23. Grodstein F, Newcomb PA, Stampfer MJ: Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analy-sis. AmJ Med 1999; 106: 574-82.
24. Tsilidis KK, Allen NE, Key TJ, et al.: Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2011; 128: 1881-9.